Increased Risk for Hip Fractures among Patients with Cholangitis: A Nationwide Population-Based Study

Table 1

Comparison of demographic profiles and history of comorbidities in cholangitis and noncholangitis cohorts.

	Cholangitis				p value
	No (N=10915)		Yes (N=2735)
	n	%	n	%
Sex					0.99
Women	5163	47.3	1294	47.3
Men	5752	52.7	1441	52.7
Age, year					0.99
<35	580	5.31	145	5.30
35–65	4560	41.8	1140	41.7
≥65	5775	52.9	1450	53.0
Mean (SD) ^#	63.7 (16.5)		63.9 (16.5)		0.58
Comorbidities
Hypertension	5411	49.6	1524	55.7	<.0001
Diabetes	2285	20.9	811	29.7	<.0001
Epilepsy	110	1.01	48	1.76	0.0011
IHD	2983	27.3	936	34.2	<.0001
COPD	2174	19.9	663	24.2	<.0001
Stroke	2127	19.5	689	25.2	<.0001
Live cirrhosis	172	1.58	235	8.59	<.0001
Osteoporosis	1650	15.1	417	15.2	0.8653
ESRD	82	0.75	31	1.13	0.0485
Drug used
Steroid	3308	30.3	831	30.4	0.9376

Chi-square test; ^#Student’s t-test.
IHD: ischemic heart disease; COPD: chronic obstructive pulmonary disease.
ESRD: end-stage renal disease; SD: standard deviation.